SK280265B6 - Vektor zahŕňajúci gén kódujúci bielkovinu gm-csf p - Google Patents

Vektor zahŕňajúci gén kódujúci bielkovinu gm-csf p Download PDF

Info

Publication number
SK280265B6
SK280265B6 SK5059-85A SK505985A SK280265B6 SK 280265 B6 SK280265 B6 SK 280265B6 SK 505985 A SK505985 A SK 505985A SK 280265 B6 SK280265 B6 SK 280265B6
Authority
SK
Slovakia
Prior art keywords
csf
protein
vector
cells
gene
Prior art date
Application number
SK5059-85A
Other languages
English (en)
Slovak (sk)
Other versions
SK505985A3 (en
Inventor
Steven C. Clark
Randal J. Kaufman
Gordon G. Wong
Elizabeth A. Wang
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27417446&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK280265(B6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of SK505985A3 publication Critical patent/SK505985A3/sk
Publication of SK280265B6 publication Critical patent/SK280265B6/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Steroid Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Detergent Compositions (AREA)
  • Fats And Perfumes (AREA)
  • Debugging And Monitoring (AREA)
SK5059-85A 1984-07-06 1985-07-05 Vektor zahŕňajúci gén kódujúci bielkovinu gm-csf p SK280265B6 (sk)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62834284A 1984-07-06 1984-07-06
US65244784A 1984-09-19 1984-09-19
US65274284A 1984-09-19 1984-09-19

Publications (2)

Publication Number Publication Date
SK505985A3 SK505985A3 (en) 1999-10-08
SK280265B6 true SK280265B6 (sk) 1999-10-08

Family

ID=27417446

Family Applications (1)

Application Number Title Priority Date Filing Date
SK5059-85A SK280265B6 (sk) 1984-07-06 1985-07-05 Vektor zahŕňajúci gén kódujúci bielkovinu gm-csf p

Country Status (28)

Country Link
EP (2) EP0337359B1 (no)
JP (4) JP2540509B2 (no)
KR (1) KR910001809B1 (no)
AT (2) ATE67244T1 (no)
AU (3) AU599572B2 (no)
CA (2) CA1341618C (no)
CY (1) CY1629A (no)
DE (3) DE3584089D1 (no)
DK (2) DK168709B1 (no)
ES (1) ES8701226A1 (no)
FI (1) FI108796B (no)
GR (1) GR851643B (no)
HK (2) HK111594A (no)
HU (1) HU208711B (no)
IE (2) IE930961L (no)
IL (2) IL75725A (no)
LU (1) LU88337I2 (no)
MY (1) MY102902A (no)
NL (1) NL930089I2 (no)
NO (4) NO179455C (no)
NZ (2) NZ228031A (no)
PL (1) PL153139B1 (no)
PT (1) PT80776B (no)
SA (1) SA94150015A (no)
SG (1) SG108991G (no)
SK (1) SK280265B6 (no)
UA (1) UA39161C2 (no)
WO (1) WO1986000639A1 (no)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU594014B2 (en) * 1984-03-21 1990-03-01 Research Corporation Technologies, Inc. Recombinant DNA molecules
JPS61227526A (ja) * 1984-07-25 1986-10-09 Chugai Pharmaceut Co Ltd 新規なコロニー刺激因子
ZA856108B (en) * 1984-10-29 1986-10-29 Immunex Corp Cloning of human granulocyte-macrophage colony simulating factor gene
AU588819B2 (en) * 1984-10-29 1989-09-28 Immunex Corporation Cloning of human granulocyte-macrophage colony stimulating factor gene
AU608741B2 (en) * 1984-11-20 1991-04-18 Schering Biotech Corporation cDNA clones coding for polypeptides exhibiting human granulocyte macrophage and eosinophil cellular growth factor activity
JP2512453B2 (ja) * 1985-02-05 1996-07-03 シ−タス コ−ポレ−シヨン 天然のコロニ−促進因子―１の精製
DE3681551D1 (de) * 1985-09-30 1991-10-24 Chugai Pharmaceutical Co Ltd Menschlicher granulozyten-colony stimulierender faktor.
EP0238655A4 (en) * 1985-10-03 1989-09-11 Biogen Nv POLYPEPTIDES LIKE THE GRANULOCYTE-MACROPHOUS COLONY STIMULATION FACTORS (GM-CSF) AND THEIR METHODS OF PRODUCING LARGE QUANTITIES IN MICROBIAL CELLS.
CA1295567C (en) * 1988-07-25 1992-02-11 Lawrence T. Malek Expression system for the secretion of bioactive human granulocyte, macrophage-colony stimulating factor (gm-csf) and other heterologous proteins from streptomyces
US5298603A (en) * 1985-12-21 1994-03-29 Hoechst Aktiengesellschaft GM-CSF protein, its derivatives, the preparation of proteins of this type, and their use
DE3545568A1 (de) * 1985-12-21 1987-07-16 Hoechst Ag Gm-csf-protein, seine derivate, herstellung solcher proteine und ihre verwendung
IL83003A (en) 1986-07-01 1995-07-31 Genetics Inst Factors that soak bone formation
GR871029B (en) 1986-07-14 1987-11-02 Genetics Inst Novel osteoinductive factors
US5162111A (en) * 1986-07-30 1992-11-10 Grabstein Kenneth H Treatment of bacterial diseases with granulocyte-macrophage colony stimulating factor
EP0256843A1 (en) * 1986-08-11 1988-02-24 Cetus Corporation Expression of g-csf and muteins thereof and their use
GB8624899D0 (en) * 1986-10-17 1986-11-19 Sandoz Ltd Monoclonal antibodies
JPH0618781B2 (ja) * 1986-10-18 1994-03-16 中外製薬株式会社 感染症治療剤
EP0276846A3 (en) * 1987-01-29 1989-07-26 Zymogenetics, Inc. Colony-stimulating factor derivatives
JP2521094B2 (ja) * 1987-04-28 1996-07-31 アムジェン、インコーポレーテッド ヒト顆粒球マクロファ―ジコロニ―刺激因子をコ―ドする合成ｄｎａ、そのｄｎａを含むプラスミド、およびそのｄｎａで形質転換された大腸菌
JPH03500481A (ja) * 1987-06-25 1991-02-07 イミュネックス・コーポレーション ウシ顆粒球マクロファージコロニー刺激因子
US5391706A (en) * 1987-07-16 1995-02-21 Schering Plough Corporation Purification of GM-CSF
ES2034239T3 (es) * 1987-07-16 1993-04-01 Schering Corporation Purificacion de gm-csf.
AU626530B2 (en) * 1987-07-17 1992-08-06 Schering Biotech Corporation Human granulocyte-macrophage colony stimulating factor and muteins thereof
CA1335717C (en) * 1987-07-17 1995-05-30 Takashi Yokota Human granulocyte-macrophage colony stimulating factor and muteins thereof
AU2251488A (en) * 1987-07-24 1989-03-01 Cetus Corporation Production of biologically active forms of csf using a baculovirus (acnpv)-insect cell expression system
EP0347057A1 (en) * 1988-05-31 1989-12-20 Schering Biotech Corporation Method of treating myeloid leukemias
AU618283B2 (en) * 1988-10-10 1991-12-19 Instituto Nazionale Per Lo Studio E La Cura Dei Tumori The use of GM-CSF in the treatment of a patient requiring high-dose chemo- or radiotherapy for cancer
US5811523A (en) 1988-11-10 1998-09-22 Trinchieri; Giorgio Antibodies to natural killer stimulatory factor
JPH0322973A (ja) * 1989-01-19 1991-01-31 Wan Shen-Yuan ヒトヘパトーム細胞系によるコロニー形成促進因子（ＣＳＦｓ）の構成性産生
HUT63181A (en) * 1989-07-14 1993-07-28 Schering Corp Process for producing gm-csf antagonists originating from carboxy terminal of gm-csf
AU3657893A (en) 1992-02-28 1993-09-13 Board Of Regents, The University Of Texas System Compositions and methods for the treatment of thermal injury
US6004807A (en) * 1992-03-30 1999-12-21 Schering Corporation In vitro generation of human dendritic cells
US6057133A (en) * 1992-11-24 2000-05-02 G. D. Searle Multivariant human IL-3 fusion proteins and their recombinant production
US5772992A (en) * 1992-11-24 1998-06-30 G.D. Searle & Co. Compositions for co-administration of interleukin-3 mutants and other cytokines and hematopoietic factors
US7091319B1 (en) 1992-11-24 2006-08-15 Bauer S Christopher IL-3 variant hematopoiesis fusion protein
US6361976B1 (en) 1992-11-24 2002-03-26 S. Christopher Bauer Co-administration of interleukin-3 mutant polypeptides with CSF'S for multi-lineage hematopoietic cell production
US6153183A (en) * 1992-11-24 2000-11-28 G. D. Searle & Company Co-administration of interleukin-3 mutant polypeptides with CSF's or cytokines for multi-lineage hematopoietic cell production
US6413509B1 (en) 1992-11-24 2002-07-02 S. Christopher Bauer Methods of ex-vivo expansion of hematopoietic cells using interleukin-3 mutant polypeptides with other hematopoietic growth factors
US6361977B1 (en) 1992-11-24 2002-03-26 S. Christopher Bauer Methods of using multivariant IL-3 hematopoiesis fusion protein
US6403076B1 (en) 1992-11-24 2002-06-11 S. Christopher Bauer Compositions for increasing hematopoiesis with interleukin-3 mutants
US5738849A (en) * 1992-11-24 1998-04-14 G. D. Searle & Co. Interleukin-3 (IL-3) variant fusion proteins, their recombinant production, and therapeutic compositions comprising them
WO1994026892A1 (en) 1993-05-12 1994-11-24 Genetics Institute, Inc. Bmp-11 compositions
DE69331268T2 (de) * 1993-06-30 2002-06-13 Lucky Ltd Modifizierte-Granulocyte-Makrophage-Kolonie-stimulierender-Faktor-Gen und seine Expression in Hefe
US6027919A (en) 1993-12-07 2000-02-22 Genetics Institute, Inc. BMP-12 and BMP-13 proteins and DNA encoding them
US5578301A (en) * 1993-12-14 1996-11-26 Sandoz Ltd. Method for using GM-CSF to reduce the acute phase response in a patient being administered IL-6 therapy
US5599536A (en) * 1993-12-13 1997-02-04 Sandoz Ltd. Method for suppressing the acute phase response in a patient receiving IL-6 therapy
US6165748A (en) 1997-07-11 2000-12-26 Genetics Institute, Inc. Frazzled nucleotide sequences and expression products
US6676937B1 (en) 1998-03-09 2004-01-13 Caritas St. Elizabeth's Medical Center Of Boston Inc. Compositions and methods for modulating vascularization
DE19905501B4 (de) 1999-02-10 2005-05-19 MediGene AG, Gesellschaft für molekularbiologische Kardiologie und Onkologie Verfahren zur Herstellung eines rekombinanten Adeno-assoziierten Virus, geeignete Mittel hierzu sowie Verwendung zur Herstellung eines Arzneimittels
JP2002536404A (ja) * 1999-02-12 2002-10-29 ワシントン ユニバーシティー 炎症性腸疾患を治療するための好中球機能の刺激
US6869762B1 (en) 1999-12-10 2005-03-22 Whitehead Institute For Biomedical Research Crohn's disease-related polymorphisms
AU2258601A (en) * 1999-12-10 2001-06-18 Ellipsis Biotherapeutics Corporation Ibd-related polymorphisms
US6689599B1 (en) 2000-10-20 2004-02-10 Genetics Institute, Llc Aggrecanase molecules
TWI329129B (en) 2001-02-08 2010-08-21 Wyeth Corp Modified and stabilized gdf propeptides and uses thereof
WO2003012038A2 (en) 2001-07-27 2003-02-13 Wyeth Aggrecanase molecules
EP1476545A4 (en) 2002-01-31 2006-11-29 Wyeth Corp AGGRECANASEMOLEKÜLE
CA2475329A1 (en) 2002-02-05 2003-08-14 Katy E. Georgiadis Truncated aggrecanase molecules
EP1525307A2 (en) 2002-07-29 2005-04-27 Wyeth Modified adamts4 molecules and method of use thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4428632A (en) * 1979-08-10 1984-01-31 Thomas & Betts Corporation Coaxial cable transition connector
JPS6030654B2 (ja) * 1980-12-31 1985-07-17 株式会社林原生物化学研究所 ヒトコロニ−刺激因子の製造方法
US4438032A (en) 1981-01-30 1984-03-20 The Regents Of The University Of California Unique T-lymphocyte line and products derived therefrom
JPH0751511B2 (ja) * 1982-03-15 1995-06-05 味の素株式会社 インターロイキン２を含有してなる癌治療剤
AU594014B2 (en) * 1984-03-21 1990-03-01 Research Corporation Technologies, Inc. Recombinant DNA molecules
AU588819B2 (en) * 1984-10-29 1989-09-28 Immunex Corporation Cloning of human granulocyte-macrophage colony stimulating factor gene
ZA856108B (en) * 1984-10-29 1986-10-29 Immunex Corp Cloning of human granulocyte-macrophage colony simulating factor gene

Also Published As

Publication number Publication date
IL75725A0 (en) 1985-11-29
NO307348B1 (no) 2000-03-20
AU644359B2 (en) 1993-12-09
NZ228031A (en) 1991-12-23
NO860775L (no) 1986-03-13
AU5497690A (en) 1990-09-13
JP2594768B2 (ja) 1997-03-26
IE60819B1 (en) 1994-08-10
DK102886D0 (da) 1986-03-06
AU599572B2 (en) 1990-07-26
NL930089I1 (nl) 1993-10-01
CY1629A (en) 1992-07-10
KR860700264A (ko) 1986-08-01
EP0188479A1 (en) 1986-07-30
FI108796B (fi) 2002-03-28
JP2594743B2 (ja) 1997-03-26
NO314941B1 (no) 2003-06-16
HU208711B (en) 1993-12-28
FI860308A0 (fi) 1986-01-22
JPH06319557A (ja) 1994-11-22
PL153139B1 (en) 1991-03-29
NO1996016I1 (no) 1996-12-18
DE3588199D1 (de) 1998-11-26
IL94754A0 (en) 1991-04-15
ES8701226A1 (es) 1986-11-16
AU628069B2 (en) 1992-09-10
KR910001809B1 (ko) 1991-03-26
NL930089I2 (nl) 1994-07-01
PL254400A1 (en) 1986-06-17
SK505985A3 (en) 1999-10-08
NO961452D0 (no) 1996-04-12
NO179455C (no) 1996-10-09
PT80776B (pt) 1987-09-30
JPH07163351A (ja) 1995-06-27
NO943300D0 (no) 1994-09-07
IE930961L (en) 1986-01-06
DK168709B1 (da) 1994-05-24
ATE172494T1 (de) 1998-11-15
EP0337359A3 (en) 1990-02-07
DK102886A (da) 1986-03-06
AU4545685A (en) 1986-02-10
GR851643B (no) 1985-11-26
NO179455B (no) 1996-07-01
DE3584089D1 (de) 1991-10-17
LU88337I2 (fr) 1994-05-04
FI860308A (fi) 1986-01-22
DE3588199T2 (de) 1999-04-08
ES544868A0 (es) 1986-11-16
JP2594744B2 (ja) 1997-03-26
NZ212645A (en) 1990-02-26
NO961452L (no) 1996-04-12
HK1011709A1 (en) 1999-07-16
EP0337359B1 (en) 1998-10-21
AU4009089A (en) 1989-12-07
MY102902A (en) 1993-03-31
DK59493A (da) 1993-05-21
PT80776A (en) 1985-08-01
IE851695L (en) 1986-01-06
HUT38675A (en) 1986-06-30
NO943300L (no) 1986-03-13
CA1340852C (en) 1999-12-14
IL75725A (en) 1993-02-21
EP0337359A2 (en) 1989-10-18
SA94150015A (ar) 2005-12-03
HK111594A (en) 1994-10-21
DE188479T1 (de) 1987-05-21
EP0188479B1 (en) 1991-09-11
JPS61502682A (ja) 1986-11-20
CA1341618C (en) 2011-07-19
JP2540509B2 (ja) 1996-10-02
DK59493D0 (da) 1993-05-21
DK172679B1 (da) 1999-05-17
JPH06199897A (ja) 1994-07-19
UA39161C2 (uk) 2001-06-15
ATE67244T1 (de) 1991-09-15
WO1986000639A1 (en) 1986-01-30
SA94150015B1 (ar) 2004-09-04
SG108991G (en) 1992-03-20

Similar Documents

Publication Publication Date Title
SK280265B6 (sk) Vektor zahŕňajúci gén kódujúci bielkovinu gm-csf p
JP3276933B2 (ja) エリスロポエチン活性を有する糖蛋白質の製造方法
US5908763A (en) DNA encoding GM-CSF and a method of producing GM-CSF protein
HU204890B (en) Process for producing human interleukin-3 and its muteins
RU2130493C1 (ru) Способ получения белка с активностью gm-csf приматов
US5106733A (en) Bovine granulocyte-macrophage colony stimulating factor
JPH0657152B2 (ja) Ｃｓｆ遺伝子類
CZ285023B6 (cs) Vektor zahrnující gen kódující bílkovinu GM-CSF primátů, hostitelská buňka, která je jím transformována, a způsob výroby bílkoviny GM-CSF primátů za jejího použití
AU602097B2 (en) Bovine granulocyte-macrophage colony stimulating factor
JPS62500424A (ja) 赤血球の増強活性を有する蛋白質のための遺伝子を含有するベクタ−および前記蛋白質を生産するための組み換えｄｎａ法
HU204086B (en) Process for producing non-human mammal animal interferons, dna sequemces coding form them and pharmaceutical compositions comprising sand interferons